Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.

Saved in:
Bibliographic Details
Title: Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Authors: Dadi N; Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, U.S.A., Stanley M; Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, U.S.A., Shahda S; Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, U.S.A., O'Neil BH; Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, U.S.A., Sehdev A; Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, U.S.A. asehdev@iupui.edu.; Center for Health Services Research, Regenstrief Institute, Indianapolis, IN, U.S.A.; Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN, U.S.A.
Source: Anticancer research [Anticancer Res] 2017 Oct; Vol. 37 (10), pp. 5533-5539.
Publication Type: Journal Article; Review
Journal Info: Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet ISSN: 1791-7530 (Electronic) Linking ISSN: 02507005 NLM ISO Abbreviation: Anticancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1791-7530
DOI:10.21873/anticanres.11985